LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.
Authors
Adebahr, SCollette, S
Shash, E
Lambrecht, M
Le Pechoux, C
Faivre-Finn, Corinne
De Ruysscher, D
Peulen, H
Belderbos, J
Dziadziuszko, R
Fink, C
Guckenberger, M
Hurkmans, C
Nestle, U
Affiliation
Department of Radiation Oncology, University Medical Center Freiburg, Freiburg, GermanyIssue Date
2015-07
Metadata
Show full item recordAbstract
Evidence supports stereotactic body radiotherapy (SBRT) as a curative treatment option for inoperable early stage non-small-cell lung cancer (NSCLC) resulting in high rates of tumour control and low risk of toxicity. However, promising results are mainly derived from SBRT of peripheral pulmonary lesions, whereas SBRT for the central tumours can lead to severe radiation sequelae owing to the spatial proximity to the serial organs at risk. Robust data on the tolerance of mediastinal structures to high-dose hypofractionated radiation are limited; furthermore, there are many open questions regarding the efficiency, safety and response assessment of SBRT in inoperable, centrally located early stage NSCLC, which are addressed in a prospective multicentre study [sponsored by the European Organization for Research and Treatment of Cancer (EORTC 22113-08113-LungTech)]. In this review, we summarize the current status regarding SBRT for centrally located early stage NSCLC that leads to the rationale of the LungTech trial. Outline and some essential features of the study with focus on a summary of current experiences in dose/fraction-toxicity coherences after SBRT to the mediastinal structures that lead to LungTech normal tissue constraints are provided.Citation
LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. 2015, 88 (1051):20150036 Br J RadiolJournal
The British Journal of RadiologyDOI
10.1259/bjr.20150036PubMed ID
25873481Type
ArticleLanguage
enISSN
1748-880Xae974a485f413a2113503eed53cd6c53
10.1259/bjr.20150036
Scopus Count
Collections
Related articles
- Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results.
- Authors: Levy A, Adebahr S, Hurkmans C, Ahmed M, Ahmad S, Guckenberger M, Geets X, Lievens Y, Lambrecht M, Pourel N, Lewitzki V, Konopa K, Franks K, Dziadziuszko R, McDonald F, Fortpied C, Clementel E, Fournier B, Rizzo S, Fink C, Riesterer O, Peulen H, Andratschke N, McWilliam A, Gkika E, Schimek-Jasch T, Grosu AL, Le Pechoux C, Faivre-Finn C, Nestle U
- Issue date: 2024 Sep
- Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours - a clinical physics perspective.
- Authors: Lambrecht M, Melidis C, Sonke JJ, Adebahr S, Boellaard R, Verheij M, Guckenberger M, Nestle U, Hurkmans C
- Issue date: 2016 Jan 20
- Comment on "Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results".
- Authors: Xu Z, Jiang J, Guo H, Zhao D, Liu S
- Issue date: 2024 Oct
- A Response to the Letter to the Editor: "Comment on Stereotactic Body Radiotherapy for Centrally Located Inoperable Early Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results".
- Authors: Levy A, Adebahr S, Hurkmans C, Fortpied C, Le Pechoux C, Faivre-Finn C, Nestle U
- Issue date: 2024 Oct
- Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial.
- Authors: Swaminath A, Wierzbicki M, Parpia S, Wright JR, Tsakiridis TK, Okawara GS, Kundapur V, Bujold A, Ahmed N, Hirmiz K, Kurien E, Filion E, Gabos Z, Faria S, Louie AV, Owen T, Wai E, Ramchandar K, Chan EK, Julian J, Cline K, Whelan TJ
- Issue date: 2017 Mar